Provided by Tiger Trade Technology Pte. Ltd.

Dyadic International, Inc.

0.8410
+0.00800.96%
Volume:753.00
Turnover:633.27
Market Cap:30.43M
PE:-3.78
High:0.8410
Open:0.8410
Low:0.8410
Close:0.8330
52wk High:1.73
52wk Low:0.7110
Shares:36.19M
Float Shares:25.32M
Volume Ratio:0.83
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2222
EPS(LYR):-0.1981
ROE:-244.15%
ROA:-39.72%
PB:11.67
PE(LYR):-4.24

Loading ...

Dyadic International Extends Convertible Note Maturity and Sets New Conversion Price

Reuters
·
Dec 30, 2025

Dyadic International Expands Collaboration With Fermbox Bio to Accelerate Animal-Free Protein Commercialization

Reuters
·
Dec 17, 2025

Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

THOMSON REUTERS
·
Dec 17, 2025

Dyadic International Signs Commercial Agreement with Opes Diagnostics for Recombinant Protein Distribution

Reuters
·
Dec 15, 2025

BRIEF-Dyadic International Inc - Co And Brig Bio Sign Development And Commercialization Agreement

Reuters
·
Dec 01, 2025

Dyadic International and BRIG BIO Sign Agreement to Develop Animal-Free Bovine Alpha-Lactalbumin

Reuters
·
Dec 01, 2025

Dyadic International, Inc. Q3 EPS USD -0.06

THOMSON REUTERS
·
Nov 13, 2025

Dyadic International Q3 EPS $(0.06) Misses $(0.04) Estimate, Sales $1.165M Beat $1.100M Estimate

Benzinga
·
Nov 13, 2025

Press Release: Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

Dow Jones
·
Nov 13, 2025

Dyadic International, ERS Genomics announces CRISPR/Cas9 license

TIPRANKS
·
Nov 10, 2025

BRIEF-Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

Reuters
·
Nov 10, 2025

Dyadic Applied BioSolutions: Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License With Ers Genomics

THOMSON REUTERS
·
Nov 10, 2025

Dyadic Applied BioSolutions: Financial Details of Agreement Were Not Disclosed

THOMSON REUTERS
·
Nov 10, 2025

Dyadic International Inc. to Release Third Quarter 2025 Financial Results

Reuters
·
Oct 29, 2025

Dyadic International Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $3

THOMSON REUTERS
·
Oct 23, 2025

Dyadic International Inc. Achieves Milestones in Partnerships with Proliant Health & Biologicals and Inzymes ApS, Advancing Commercialization Efforts

Reuters
·
Oct 08, 2025

Dyadic International Achieves Key Scientific Milestones in Recombinant Protein Production, Advancing Commercialization Efforts

Reuters
·
Oct 06, 2025

Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments

GlobeNewswire
·
Oct 06, 2025

Dyadic International Inc. to Present at BioProcess International BPI East Conference

Reuters
·
Sep 04, 2025

Dyadic Q2 2025 Earnings Call Summary and Q&A Highlights: Strategic Shift to Revenue-Driven Biotechnology

Earnings Call
·
Aug 14, 2025